Sofosbuvir-velpatasvir-voxilaprevir provides salvage therapy for NS5A failures
Despite the availability of new, highly successful direct-acting antiviral (DAA) regimens, more than one third of chronic hepatitis C (HCV) patients are denied access to treatment by their insurance provider, according to a new study.
Those using illicit drugs and co-infected with HIV and hepatitis C are willing to use direct-acting anti-viral agents, says a new study.
Hispanic and Asian patients have a higher risk of cirrhosis and liver cancer, but direct-antiviral treatment eliminates ethnic disparities.
Targeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.
Researchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
Week 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.
The benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Direct-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
A new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.